Stem cell medicinal products cGMP and cGTP

Stem cell medicinal products cGMP and cGTP

2020-08-05T08:51:50+00:00July 7th, 2020|

Background

The use of stem cells for therapeutic and clinical applications is a fast growing area in Biotech research and development. Stem cells have the potential to differentiate into specific cell types which can be used to repair or replace damaged cells, tissues and organs. This vast field of research, the potential therapeutic treatments, the rapid expansion of new technologies (such as human cell bio-reactors) and the blurring of the boundary between research and clinical therapy requires a broad and comprehensive regulatory framework in order to deal with the unique hazards and limitations of production, manufacturing and distribution of cell therapy based products. This article summarizes US regulations and guidelines regarding cells, tissues and cellular & tissue based products (HCT/Ps). Regulation of stem cell therapy and products in the EU according to the EMA directives are not within scope of this article.

Our services

Code of Federal Regulations

In the US, use of cell therapy products is codified within the following sections of the Code of Federal Regulations:

  • IND regulations (21 CFR 312)
  • Biologics regulations (21 CFR 600)
  • cGMP (21 CFR 211)
  • cGTP (21 CFR 1271)

351 and 361 cell therapy products

US federal regulation on cellular therapy is divided into two sections of the Public Health Service Act (PHSA), referred as “351 products” and “361 products”.

  • “351 products”

“351 products” are manipulated and gene-modified cell based products (cultured cells, CTLs, tumor vaccines etc.) that are used in a non-homologous way for a different function in comparison to their original purpose, such as bone marrow cells used for heart disease treatment and/or a non-autologous use on a different individual/s than the cell donor. As such, 351 products are considered a higher risk, are regulated and registered as an Investigational New Drug (IND) and treated as a biological products under cGMP guidelines. In addition, these products are required to comply with sub parts B (Procedures for Registration and Listing), C (Donor Eligibility) & D (Current Good Tissue Practice) of 21 CFR 1271.

  • “361 products”

“361 products” are traditional blood and bone marrow progenitor cells as well as other cells, minimally manipulated for transplantation. These products are intended for homologous use, with no combinations of cells/tissues and intended for autologous treatment (or allogenic use in first degree relatives). Minimal manipulation is defined as processing that does not alter cell-/tissue-relevant biological characteristics. These products may or may not have a systemic effect but are for analogous use. 361 products are considered a lower risk (compared to 351 products) and as such do not require FDA pre-market review. Since not directly covered under the current  good manufacturing practice (cGMP) guidelines, 361 products are regulated under title 21 CFR 1271 for current good tissue practice (cGTP). Specified guidelines concerning 361 products mainly deal with prevention of communicable diseases, infection and donor eligibility requirements. Products such as blood and blood components, minimally manipulated bone marrow, organs for transplant and secreted products are not considered HCT/Ps and are not regulated under cGMP or cGTP guidelines. All human cell based products, in addition to being regulated under the broader cGMP guidelines, are regulated under Title 21 CFR 1271 covering the cGTP guidelines. As a rule, a conflict between regulations will be resolved by adhering to the more specific and detailed guideline. Title 21 CFR 1271, “Human Cells, Tissues, and Cellular & Tissue-Based Products”, is categorized as follows:

  • Subpart A-General Provisions
  • Subpart B-Procedures for Registration and Listing
  • Subpart C-Donor Eligibility
  • Subpart D-Current Good Tissue Practice (cGTP)
  • Subpart E-Additional Requirements for Establishments is described in 1271.10
  • Subpart F-Inspection and Enforcement of Establishments is described in 1271.10

cGTP guidelines core requirements (1271, sub part D) are categorized as follow:

  • Exemptions/alternatives [1271.155]
  • Quality Program [1271.160]
  • Personnel [1271.170]
  • Procedures [1271.180]
  • Facilities [1271.190 (a) and (b)]
  • Environmental control [1271.195 (a)]
  • Environmental monitoring [1271.195 (c) through (h)]
  • Equipment [1271.200 (a)]
  • Supplies and reagents [1271.210 (a) and (b)]
  • Recovery [1271.215]
  • Processing/process controls [1271.220]
  • Process changes [1271.225]
  • Process Validation [1271.230]
  • Labeling controls [1271.250 (a) and (b)]
  • Storage [1271.260]
  • Receipt, pre-distribution shipment, and distribution [1271.265 (a) through (d)]
  • Records [1271.270 (e)]
  • Tracking [1271.290 (a) through (g)]
  • Complaint file [1271.320]

 

Research and development

Consultancy in a variety of areas including design, research labs and clean rooms, development technologies, investor business presentations, regulatory strategy, market analysis, clinical trial protocols, GLP, GCP, ISO 17025, calibration, CMC, professional training.

read more

Design and engineering

Designing factories, clean rooms and laboratories, engineering documentation, certification, technology selection, process engineering, and validation with a combination of theoretical knowledge, practical experience, and in-depth understanding of the biometrics regulation and principles and in accordance with the GxP principles.

read more

Manufacture and packaging

Consultancy in manufacturing plant design, development and engineering of manufacturing processes, selecting the most appropriate technology, process gable, technology transfer, GMP, process improvement, utilization optimization and improvement, employee training and equipment validation, systems, production processes and cleaning.

read more

GXP, Quality Validation

Advises, establishes, accompanies and upgrades systems of various types of quality management, executes GMP trainings and courses, assimilates the company’s GxP principles, ISO 13485, assures quality and prepares for global regulatory audits while conducting risk analysis and evaluation, equipment, systems, software, testing methods, manufacturing processes. And cleanliness until successfully audited.

read more

Regulation and registration

Regulatory consulting and drug registration, EMC, CE Mark, nutritional and cosmetic supplements in Israel and worldwide, building a smart regulatory strategy, helping to prepare documents and requirements in a professional manner, in a short time, outlining the product, shelf life and graphics, import certifications and meetings with regulatory bodies and up to approval .

read more

Software and systems

Digital healthcare consulting, software development and medical applications in accordance with 21CFR part 11 / Annex 11 / HIPAA / GDPR requirements, ISO 13485/27001/27799, CE marking, Risk Assessment, and software validation and control systems up to marketing approval.

read more

Cell therapy products Good Manufacturing Practice/Good Tissue Practice

General

For cell therapy basic research purposes, Good Laboratory Practice (GLP) can be sufficient for this specific stage. On the other hand, for cell therapy clinical trials, good clinical practice (GCP) is required. For cell therapy products manufacturing, Good manufacturing Practice (GMP) and Good Tissue Practice (GTP) are both required. In general, GMP guidelines cover areas such as documentation, validation, facilities, equipment & systems, personnel, training, controlled documentation management, manufacturing, process control, labeling, packaging, storage, distribution etc. The title 21 code of federal regulations (CFR) includes GMP guidelines that cover the various GMP areas detailed below:

  • Part 210- cGMP for manufacturing, processing, packaging and storage of drug products.
  • Part 211- cGMP for finished pharmaceutical products.
  • Part 225- cGMP for medicated feed.
  • Part 226- cGMP for type A medicated articles.
  • Part 606- cGMP for blood and blood components.

Cell therapy products GMP

Cell therapy medicinal products are covered under cGMP regulation for finished pharmaceutical products. The GMP requirements are divided into the following areas:

Facility

  • Mix up
  • Area definition
  • Facility construction

Personnel

  • Numbers and functions
  • Responsibilities and background
  • Training and assessments

Documentation

  • Document control
  • Trace ability
  • Good Documentation Practice
  • Product identification and characterization

Equipment

  • Operation
  • Maintenance
  • Sanitary design
  • Cleaning
  • Qualification and Validation
  • Software verification and validation

Production and process controls

  • Standard Operation Procedures (SOPs)
  • Donor suitability criteria
  • Sterile collection methods validation
  • Product-donor relation methods
  • Collection procedures
  • Product preparation
  • In process and final product testing
  • Final product storage and distribution
  • Product administration methods

לפרטים נוספים






For further details






21 CFR part 1271 regulations

In May 2005, 21 CFR part 1271 regulations were published in order to close this gap, related to human cells, tissues and cellular tissue based products (HCT/Ps). HCT/Ps do not include “vascularized organs” for transplant, blood components, secreted/extracted products, minimally manipulated bone marrow which are not combined with another article, ancillary products, animal cells, tissues and in vitro diagnostics. These guideline includes donor eligibility, current Good tissue Practices, requirements, inspection and enforcement. 361 and 351 type cell therapy products must comply the 21 CFR part 1271 requirements. 4.4  Good Tissue Practice (GTP)

 GTP scope

cGTP standards were established for communicable disease prevention, introduction and transmission which can be caused by microorganisms such as bacteria, virus, fungi and parasites. cGTP requirements are divided into areas such as facilities, environmental control, equipment, material and reagents, covery, processing, process controls, labeling, storage and distribution etc.

GTP Quality System

Quality System should include communicable disease Risk Assessment in order to eliminate/reduce the potential risk. Moreover, Quality System should cover the following issues:

  • Documentation
  • Deviations documentation and investigations (including root cause analysis)
  • Corrective And Preventive Actions (CAPA)
  • Change Control
  • Complaint handling
  • Calibration
  • Validation
  • Control and monitoring for critical parameters
  • Personnel education, training and qualification
  • Facility and clean room design, maintenance, cleaning
  • Environmental controls
  •  HVAC/clean room validation
  • Equipment design, operation, maintenance, cleaning and validation
  • Computerized System and Software Validation
  • Contamination, cross contamination and mix-up
  • Process Performance Qualification (PPQ)
  • Pathogen inactivation validation
  • Labeling controls
  • Storage controls
  • Distribution controls

Biochem has been advising biomedical companies for more than 13 years.
Contact us for pharmaceutical research and development consulting services.
To get in touch, click here
072-2337710
[email protected]

Articles we wrote for your use

CE Annex 11, FDA 21 CFR Part 11: Computerized systems and software validation

What is software validation? Software validation is part of the computerized systems validation (CSV) process. Computerized systems validation is defined as documented evidence with a high degree of assurance [...]

Good weighing practice (GWP) for laboratory and production balances

Introduction Weighing of raw materials, products, reagents, excipients and other product related materials is an area which has risks in the biotechnology and pharmaceutical industries. Any weighing mistake which [...]

Good Storage and Distribution Practice (GSP/GDP), cold chain safety and validation

Background Good Storage Practice (GSP) and Good Distribution Practice (GDP) describe human, veterinary and investigational drug substance and drug product supply chain procedures and standards for assurance of the [...]

More articles for you

You are invited to contact us

צור קשר





WhatsApp chat